Cancer and cardiovascular disease are the two major causes of morbidity and mortality in worldwide. Discovering new therapeutic agents for the management of breast cancer (BC) has increased the numbers of cancer survivors but with the risk of cardiovascular adverse events (CV-AEs). All drugs can potentially damage the cardiovascular system, with different types of clinical manifestations from ischemic myocardial disease to vasculitis, thrombosis or pericarditis. An early detection of CV-AEs guarantees an earlier treatment, which is associated with better outcomes. Cardio-oncology field enlarged its studies to improve prevention, monitoring and treatment of all cardiotoxic manifestations related to old or modern oncological agents. A multidisciplinary approach with a close partnership between oncologists and cardiologists is essential for an optimal management and therapeutic decision-making. The aim of this chapter is to review all types of cardiotoxic manifestations related to novel and old agents approved for treatment of BC patients including chemotherapy, anti-HER2 agents, cyclin-dependent kinase 4/6 inhibitors, PolyADP-ribose polymerase (PARP) inhibitors, antiangiogenic drugs and immunotherapy. We also focused our discussion on prevention, monitoring, treatment, and management of CV-AEs.
Keyphrases
- cardiovascular disease
- decision making
- dna damage
- oxidative stress
- chronic kidney disease
- heart failure
- newly diagnosed
- combination therapy
- squamous cell carcinoma
- end stage renal disease
- dna repair
- radiation therapy
- metabolic syndrome
- young adults
- rectal cancer
- minimally invasive
- robot assisted
- locally advanced
- papillary thyroid
- advanced cancer
- ischemia reperfusion injury
- lymph node metastasis
- cardiovascular events
- structural basis